Sanofi reported net cash proceeds of about 10 billion ($10.7 billion) from the deal, which it had outlined earlier in 2024.

Sanofi and CD&R close Opella transaction, create global consumer healthcare leader Paris, April 30, 2025. Opella today becomes an independent global leader in consumer healthcare, marking a pivotal ...

Six months after entering talks with U.S. private equity firm Clayton, Dubilier & Rice (CD&R), Sanofi has closed a deal to ...

Opella is now a standalone company. Sanofi announced today the closing of the sale to CD&R of a 50.0% controlling stake of ...

Sanofi and CD&R close Opella transaction, create global consumer healthcare leader Paris, April 30, 2025. Opella today becomes an independent global leader in consumer healthcare, marking a pivotal ...

Opella today becomes an independent global leader in consumer healthcare, marking a pivotal step in French pharma major Sanofi's strategy. Sanofi announced today the closing of the sale to US private ...

The closing of the sale of a controlling stake in Opella to CD&R is anticipated in Q2Stay Ahead of the Market: Discover outperforming ...

Sanofi has completed the sale of a 50.0% controlling stake in its consumer healthcare division, Opella, to CD&R, creating a global leader in ...

Sanofi SNY reported first-quarter 2025 adjusted earnings of 94 cents per American depositary share, which beat the Zacks Consensus Estimate of 90 cents per share. Earnings of €1.79 per share rose 17.0 ...

Enterogermina, the leading brand in the probiotic segment and part of Opella, Sanofi's Consumer Healthcare business unit, has launched a campaign that playfully challenges the laws of physics: The ...